NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1 to 25 of 1250

Display Results as:

Centers of Biomedical Research Excellence (COBRE) (P20 Clinical Trial Optional) - PAR-18-266

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 01-25-2019 

Activity Code: P20 

Summary: The National Institute of General Medical Sciences (NIGMS) invites applications for Centers of Biomedical Research Excellence (COBRE) from investigators at biomedical research institutions that award doctoral degrees in the health sciences or sciences related to health or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other federal agencies within Institutional Development Award (IDeA) eligible states. The objectives of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic multi-disciplinary center and to enhance the ability of investigators to compete independently for complementary National Institutes of Health (NIH) individual research grants or other external peer-reviewed support. COBRE awards are supported through the IDeA Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH.  

Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed) - RFA-DK-18-005

Organization: NIDDK 

Posting Date: 04-03-2018 

Expiration Date: 12-07-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for T1D. The purpose is to accelerate the discovery of function of the causal genes and variants that influence the risk for disease. 

Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required) - RFA-DA-19-005

Organization: NIDA 

Posting Date: 03-05-2018 

Expiration Date: 11-08-2018 

Activity Code: R61/R33 

Summary: This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement. 

Interdisciplinary Research Teams to Investigate Reciprocal Basic Behavioral and Social Linkages Between Sleep and Stress (R24 Clinical Trial Optional) - PAR-18-694

Organization: OD 

Posting Date: 03-02-2018 

Expiration Date: 11-30-2018 

Activity Code: R24 

Summary: This FOA encourages applications that develop, strengthen, and evaluate transdisciplinary approaches, methods, and investigative teams in basic behavioral, social, and/or biobehavioral research to generate fundamental knowledge of the reciprocal linkages between sleep and stress. Stress can result in sleep disruption due to both psychological as well as physiological changes. Sleep disruption can result in physiological changes; however, individuals may not recognize or identify impairment due to sleep disruption. This initiative supports the development of research teams to understand how basic individual, social, biological, and environmental factors interact in a dynamic relationship between sleep patterns and psychosocial stress to influence health, wellness, disease, and/or treatment adherence. 

Making Health Care Safer in Ambulatory Care Settings and Long Term Care Facilities (R18) - PA-18-750

Organization: AHRQ 

Posting Date: 04-10-2018 

Expiration Date: 09-08-2021 

Activity Code: R18 

Summary: The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) works to ensure patient safety in multiple settings with recent efforts to increase the development of processes including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting and long term care facilities. This Funding Opportunity Announcement (FOA) will fund large research demonstration and implementation projects that pertain to ambulatory care settings and long term care facilities with a focus on implementing evidence-based processes to improve patient safety, especially those involving transitions in care. AHRQ is interested in studies in these two settings that develop, utilize, and evaluate strategies to implement existing measures, metrics, tools or practices that have already been validated and have been shown to be efficacious in improving patient safety sites. 

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) - PAR-18-226

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 10-20-2018 

Activity Code: DP1 

Summary: Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. 

Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed) - PA-18-718

Organization: NIAMS 

Posting Date: 03-28-2018 

Expiration Date: 09-08-2021 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. 

Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed) - PA-18-719

Organization: NIAMS 

Posting Date: 03-28-2018 

Expiration Date: 09-08-2021 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. 

Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 Clinical Trial Optional) - PAR-18-265

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 10-03-2019 

Activity Code: U54 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support the development of infrastructure and other resources required for the conduct of Clinical and Translational Research (CTR) in IDeA-eligible states. IDeA-CTR Centers are expected to provide added value to the biomedical research efforts in the participating institutions through support of activities that cannot easily be provided through standard research grant awards. The proposed activities will provide the infrastructure and resources that will enhance the competitiveness of the investigators to obtain additional funding for clinical and translational research. Applicants must establish a statewide network of collaborating and partnering institutions/organizations. Other institutions/organizations outside the state may be included if forming a network of wider reach. Since only one award will be made per IDeA-eligible state, only one application should be submitted per state. 

Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE)(P20 Clinical Trial Optional) - PAR-18-264

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 09-29-2018 

Activity Code: P20 

Summary: The National Institute of General Medical Sciences (NIGMS) of the NIH invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for National Institutes of Health (NIH) individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in IDeA states. 

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) - PAR-18-225

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 01-08-2020 

Activity Code: P30 

Summary: NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators, and share findings, data and their resources, consistent with achieving the goals of the program.  

NIH Director's Early Independence Award (DP5 - Clinical Trial Optional) - RFA-RM-18-010

Organization: RMOD 

Posting Date: 03-26-2018 

Expiration Date: 09-28-2018 

Activity Code: DP5 

Summary: The NIH Directors Early Independence Award supports exceptional investigators who wish to pursue independent research essentially directly after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications are welcome from individuals of diverse backgrounds and perspectives and in any topic of relevance to the broad mission of NIH. The NIH Directors Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. 

Advancing HIV Therapeutic Vaccine Science (U01 Clinical Trial Required) - RFA-AI-18-015

Organization: NIAID 

Posting Date: 04-25-2018 

Expiration Date: 09-28-2018 

Activity Code: U01 

Summary: This Funding Opportunity Announcement (FOA) solicits applications that will advance understanding of vaccine regimens and immune responses that sustainably suppress virus in HIV-infected individuals. The FOA will support small, multi-arm, comparative clinical trials designed to identify correlations between levels of induced immune response and HIV virologic control. Vaccines may be combined with adjuvants and/or other modifiers of the immune response to HIV. 

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) - PAR-18-224

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 01-08-2019 

Activity Code: P50 

Summary: This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.  

Examining Diversity, Recruitment and Retention in Aging Research (R24 Clinical Trial Not Allowed) - PAR-18-749

Organization: NIA 

Posting Date: 04-10-2018 

Expiration Date: 01-26-2021 

Activity Code: R24 

Summary: This funding opportunity announcement encourages collaborative teams to target gaps in methods and outcomes regarding research participant recruitment and retention. The team approach encouraged by this initiative will be used to generate a research resource to advance processes for high yield recruitment, formulate breakthrough ideas, concepts and approaches to research participant recruitment and retention, strengthen outreach and community engagement practices, and devise improved communication strategies. Teams will demonstrate the success of these improvements by engaging a large diverse population. The primary outcome will be the development of a population of diverse community members ready to engage in NIA funded clinical research studies. 

NIH Director's Pioneer Award (DP1 - Clinical Trial Optional) - RFA-RM-18-007

Organization: RMOD 

Posting Date: 04-23-2018 

Expiration Date: 09-15-2018 

Activity Code: DP1 

Summary: The NIH Directors Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative approaches to major challenges in the biomedical or behavioral sciences towards the goal of enhancing human health. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. 

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional) - PAR-18-657

Organization: NINDS 

Posting Date: 02-13-2018 

Expiration Date: 09-10-2020 

Activity Code: U54 

Summary: This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan. 

NIMH Research Education Mentoring Programs for HIV/AIDS Researchers (R25) - PAR-17-485

Organization: NIMH 

Posting Date: 09-15-2017 

Expiration Date: 09-08-2020 

Activity Code: R25 

Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). 

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R21 Clinical Trials Not Allowed) - PA-18-754

Organization: NIAID 

Posting Date: 04-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Grant (R21) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. 

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional) - PA-18-753

Organization: NIAID 

Posting Date: 04-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. 

Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional) - PAR-18-764

Organization: NIAID 

Posting Date: 04-20-2018 

Expiration Date: 05-08-2021 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. 

SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) - PA-18-705

Organization: NINDS 

Posting Date: 03-06-2018 

Expiration Date: 04-06-2021 

Activity Code: R43/R44 

Summary: This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive patent license agreement for internal research use for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public. 

Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44 Clinical Trial Not Allowed) - PA-18-708

Organization: NIMH 

Posting Date: 03-15-2018 

Expiration Date: 09-06-2021 

Activity Code: R43/R44 

Summary: The purpose of this funding opportunity is to encourage small businesses to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to better understand and manipulate the dynamic structure and/or function of brain localized G-protein coupled receptors (GPCRs) and/or potentially identify novel selective and specific agonists, antagonists, or allosteric modulators for these receptor subtypes, with a focus on mental health function or dysfunction. Technologies and approaches aimed at either well characterized receptor subtypes or understudied/orphan receptors would be of potential interest to NIMH. 

Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)-Clinical Trial Not Allowed - PA-18-709

Organization: NIMH 

Posting Date: 03-15-2018 

Expiration Date: 09-06-2021 

Activity Code: R41/R42 

Summary: The purpose of this funding opportunity is to encourage small businesses to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to better understand and manipulate the dynamic structure and/or function of brain localized G-protein coupled receptors (GPCRs) and/or potentially identify novel selective and specific agonists, antagonists, or allosteric modulators for these receptor subtypes, with a focus on mental health function or dysfunction. Technologies and approaches aimed at either well characterized receptor subtypes or understudied/orphan receptors would be of potential interest to NIMH. 

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21 Clinical Trial Optional) - PAR-18-242

Organization: FIC 

Posting Date: 11-30-2017 

Expiration Date: 09-01-2018 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to conduct research to develop or adapt innovative mobile health (mHealth) technology specifically suited for low and middle income countries (LMICs) and determine the health-related outcomes associated with implementation of the technology. Of highest interest are innovative, well-designed multidisciplinary projects that aim to generate generalizable knowledge for the field. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top